Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 244
Tipo Título / Nombre Autor(es) Año
Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study Chiappella A, Witzig E, Cocks K, Greenwood M, Williams A, Scott DW, Gascoyne RD, Yamamoto K, Jurczak W, Özcan M, Belada D, Bergua Burgues JM, Piazza F, Visco C, Musuraca G, Margunato Debay S, Czuczman M, Zhai M, Braverman J, Vitolo U, Nowakowski G 2019
Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry Bergua Burgues JM, Cano-Ferri I, Martínez Cuadron D, Boluda B, Martínez Sánchez P, Rodríguez Veiga R, Esteve J, Vives S, Serrano J, Vidriales MB, Salamero O, Carretero C, Jiménez Ubieto A, Casas I, Cardesa R, Díaz Beyá M, Brunet S, benavente C, Pérez Simón JA, Moscardo F, Aguilar E, Pérez Encinas M, López Martínez A, Rodríguez C, Cabello A, Labrador J, Costilla L, Sossa C, Bernal del Castillo T, Sanz MA, Montesinos P 2019
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial Ribera JM, Morgades M, Prob M, Ciudad J, Montesinos P, Barba P, García-Cadenas I, Moreno MJ, Vives S, Esteve J, Gil C, Monsalvo S, Artola MT, Ribera J, Genesca E, Tormo M, Cervera M, Martínez Carballeira D, Novo A, González Campos J, Soria B, Bermúdez A, López Martínez A, Mercadal S, Fernández Martín R, Coll R, Serrano J, Amigo ML, Martínez Sánchez P, Bergua JM, Serrano Maestro A, Giménez Conca A, Barrera S, Granada I, Feliu E, Orfao A 2019
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, Sanz MÁ 2019
Clinicobiologic characteristics and outcome of elderly frail patients with acute lymphoblastic leukemia included in a specific protocol (all-07FRAIL) Ribera JM, García Calduch O, Gil C, González Campos J, Moreno MJ, Barba P, Amigo ML, Martinez Carballeira D, Alonso N, Bergua JM, Mercadal S, Cladera A, Vall Llovera F, García Guinon A, López A, Lavilla E, Sierra M, Hernández Rivas JM 2019
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González AA, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P 2019
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy Sánchez-Correa B, Valhondo I, Hassouneh F, López-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, Alonso C, Solana R, Tarazona R 2019
Coexistence of ymphoplasmacytic lymphoma, multiple myeloma and myelodysplastic syndrome Cáceres Hernández S, Bañas Llanos H, Arcos Carmona MJ, Cardesa Cabrera R, Suárez Varela S, Casas Avilés I, Moriano Palacios B, Espina García M, Rodríguez López A, Ibañez Espacio F, Bermejo Vega N, Cabrera C, Carnicero González F, Bergua Burgués J 2019
LMA NPM1 tras TE JAK2V617F: ¿transformación leucémica u origen de novo? Moriano Palacios BJ, Ferre Bermejo O, Cardesa Cabrera R, Suárez-Varela Pineda S, Cáceres Hernández S, Rodríguez López A, Espina García M, Bañas Llanos H, Arcos Carmona MJ, Ibáñez Espacio F, Bermejo Vega N, Cabrera Silva C, Prieto Fernández J, Carnicero González F, Bergua Burgués JM 2019
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy Labrador J, Luño E, Vellenga E, Brunet S, González-Campos J, Chillón MC, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil C, Tormo M, Salamero O, Manso F, Fernández I, de laSerna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Cervera J, Calasanz MJ, Boluda B, Sobas M, Lowenberg B, Sanz MA, Montesinos P 2019